Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06961214 · ClinicalTrials.gov registry record · Phase 3
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
A Phase 3 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 960
- Enrollment target
- 1
- Study location
NCT06961214 is a Phase 3 study of Pulmonary Disease, Chronic Obstructive that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 960 participants, roughly in line with the 1,031-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT06961214, a Phase 3 study of Pulmonary Disease, Chronic Obstructive, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 960 participants
- Enrollment target
- 1
- Study location
Study Summary
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Depemokimab
Study Locations (1)
Florida
- GSK Investigational Site - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 960 participants |
| Start Date | 2025-06-23 |
| Est. Completion | 2029-08-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06961214
The ClinicalTrials.gov registry entry for NCT06961214 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 960 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 1,031-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06961214 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06961214 about?
NCT06961214 is a clinical study titled "Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)". Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
What is the current status of trial NCT06961214?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 960 participants. The study started on 2025-06-23. Estimated completion is 2029-08-21.
What conditions does trial NCT06961214 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT06961214?
The interventions under investigation include: Placebo (DRUG), Depemokimab (DRUG).
Who is sponsoring clinical trial NCT06961214?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06961214 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
RECRUITING · Phase 3
-
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
COMPLETED · Phase 3
-
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 3
-
Tiotropium / Respimat One-Year Study
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.